Inhalable Biologics Market size was valued at USD 3,210.0 million in 2023 and is projected to grow from USD 3,710.4 million in 2024 to USD 10,844.5 million by 2031, exhibiting a CAGR of 16.56% during the forecast period.
Recent Developments (M&A/Partnerships/Agreements/Product Launches)
In January 2025, Ethris GmbH announced positive Phase 1 results for ETH47, an mRNA-based nasal therapy for uncontrolled asthma. ETH47 showed dose-dependent interferon lambda (IFNλ) expression, confirming target engagement with no serious adverse events. Ethris plans to begin a Phase 2a trial in Q2 2025 to assess ETH47’s effect on asthma symptoms after rhinovirus infection.
Access Detailed Research @ https://www.kingsresearch.com/inhalable-biologics-market-1690
Key Companies in Inhalable Biologics Market:
- AstraZeneca
- MannKind Corporation
- Synairgen plc.
- Pulmocide
- Aerogen Ltd
- Liquidia Corporation
- Nephron Pharmaceuticals Corporation
- InCarda Therapeutics, Inc.
- Agomab Therapeutics
- Acu-Flow Limited
- ReCode Therapeutics
- AATec Medical GmbH
- Avalyn Pharma Inc.
- VERO Biotech
- Spexis Ltd.
Market Dynamics:
The inhalable biologics sector is experiencing significant momentum, propelled by several key factors:
Rising Prevalence of Respiratory Diseases: Chronic respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis are on the rise globally. Inhalable biologics offer targeted lung delivery, enhancing treatment efficacy while minimizing systemic side effects.
Technological Innovations: Advancements in formulation technologies have improved the stability and bioavailability of biologics for inhalation. Innovations such as dry powder inhalers (DPIs) and nebulizers have enhanced patient compliance and broadened therapeutic applications.
Patient Preference for Non-Invasive Therapies: The shift towards self-administration and non-invasive treatment options has increased the demand for inhalable biologics, offering convenience and improved quality of life for patients.
Regional Insights:
North America: Dominates the inhalable biologics market, driven by a high prevalence of respiratory diseases, substantial biopharma investments, and early regulatory approvals.
Asia-Pacific: Exhibiting rapid growth due to the rising prevalence of chronic respiratory diseases, expanding healthcare infrastructure, and increasing adoption of advanced therapies in countries like China, India, and Japan.
Latin America and Middle East & Africa: Witnessing growth fueled by increasing healthcare expenditures, rising awareness of advanced treatment options, and government initiatives aimed at healthcare modernization.
Future Outlook:
The inhalable biologics market is poised for substantial growth, driven by technological advancements, increasing demand for non-invasive therapies, and expanding applications across various diseases. Strategic collaborations, regulatory support, and continuous innovation will be pivotal in shaping the future landscape of this dynamic market.
About us
At the core of our mission, we strive to drive revenue impact for our clients through exceptional research strategies. With a focus on exclusivity, innovation, and real-time insights, we provide accurate, reliable, and actionable market research data. This empowers our clients to seize opportunities, navigate risks, optimize their strategies effectively, and build the businesses of tomorrow.
